Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 346

1.

Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.

Chu JJ, Rajamanonmani R, Li J, Bhuvanakantham R, Lescar J, Ng ML.

J Gen Virol. 2005 Feb;86(Pt 2):405-12.

PMID:
15659760
3.

West Nile virus is neutralized by HOCl-modified human serum albumin that binds to domain III of the viral envelope protein E.

Vossmann M, Kirst M, Ludolfs D, Schreiber M.

Virology. 2008 Apr 10;373(2):322-8. doi: 10.1016/j.virol.2007.12.008.

4.

Structural basis of West Nile virus neutralization by a therapeutic antibody.

Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH.

Nature. 2005 Sep 29;437(7059):764-9.

PMID:
16193056
5.

Peptide inhibitors of dengue virus and West Nile virus infectivity.

Hrobowski YM, Garry RF, Michael SF.

Virol J. 2005 Jun 1;2:49.

7.
8.

Rapid purification of recombinant dengue and West Nile virus envelope Domain III proteins by metal affinity membrane chromatography.

Tan LC, Chua AJ, Goh LS, Pua SM, Cheong YK, Ng ML.

Protein Expr Purif. 2010 Nov;74(1):129-37. doi: 10.1016/j.pep.2010.06.015.

PMID:
20600950
9.

A glycosylated peptide in the West Nile virus envelope protein is immunogenic during equine infection.

Hobson-Peters J, Toye P, Sánchez MD, Bossart KN, Wang LF, Clark DC, Cheah WY, Hall RA.

J Gen Virol. 2008 Dec;89(Pt 12):3063-72. doi: 10.1099/vir.0.2008/003731-0.

PMID:
19008394
10.

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116.

PMID:
21596075
11.

Antiviral peptides targeting the west nile virus envelope protein.

Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell RA, Krueger JK, Koski RA, Fikrig E.

J Virol. 2007 Feb;81(4):2047-55.

12.

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.

Desprès P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F.

J Infect Dis. 2005 Jan 15;191(2):207-14.

PMID:
15609230
14.

Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.

Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD.

Vaccine. 2008 Jan 10;26(2):153-7.

PMID:
18069096
15.

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.

16.

Inhibition of Japanese encephalitis virus infection by flavivirus recombinant E protein domain III.

Fan J, Liu Y, Xie X, Zhang B, Yuan Z.

Virol Sin. 2013 Jun;28(3):152-60. doi: 10.1007/s12250-013-3331-8.

PMID:
23709058
17.

Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus.

Ledizet M, Kar K, Foellmer HG, Bonafé N, Anthony KG, Gould LH, Bushmich SL, Fikrig E, Koski RA.

J Infect Dis. 2007 Dec 15;196(12):1741-8. doi: 10.1086/523654.

PMID:
18190253
18.

Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses.

Yu S, Wuu A, Basu R, Holbrook MR, Barrett AD, Lee JC.

Biochemistry. 2004 Jul 20;43(28):9168-76.

PMID:
15248774
19.

Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

McAuley AJ, Torres M, Plante JA, Huang CY, Bente DA, Beasley DW.

J Virol. 2016 Apr 14;90(9):4757-70. doi: 10.1128/JVI.02861-15.

Supplemental Content

Support Center